Expression of chemokine receptors CCR5 and CXCR4 on CD4+ T cells and plasma chemokine levels during treatment of active tuberculosis in HIV-1-coinfected patients.

Publication date

2005

Authors

Wolday, D.
Tegbaru, B.
Kassu, A.
Messele, T.
Coutinho, R. A.ISNI 0000000398376024
van Baarle, D.ISNI 000000038873051X
Miedema, FISNI 0000000066461142

Editors

Advisors

Supervisors

DOI

Document Type

Article

Collections

License

Abstract

The pathogenesis of persistently elevated plasma HIV viremia in patients coinfected with tuberculosis (TB) during anti-TB treatment in Africans remains unknown. We examined the expression of chemokine receptors CCR5 and CXCR4 on CD4+ T cells and plasma chemokine levels of macrophage inflammatory protein (MIP)-1a, MIP-1b, regulated on activation normal T expressed and secreted (RANTES), and stromal cell–derived factor (SDF)-1a among TB patients with HIV coinfection during the first 2 months of anti-TB treatment. During treatment of TB, the plasma HIV-1 load and CD4+ T-cell count remained unchanged. Levels of CCR5 and CXCR4 expression on CD4+ T cells as well as plasma levels of chemokines remained persistently elevated during anti-TB treatment. Persistently elevated plasma HIV viremia also paralleled persistently elevated expressions of activated CCR5+ or CXCR4+ CD4+ T cells. These results suggest that increased expression of CCR5 and CXCR4 on an activated CD4+ T-cell population coupled with persistently elevated chemokines may provide a suitable condition for continuous replication of HIV associated with TB coinfection. This, in turn, may contribute, at least in part, to the observed persistently elevated plasma HIV viremia in coinfected patients despite anti-TB treatment.

Keywords

CD4+, CCR5, CXCR4, chemokines, HIV, tuberculosis, Africa, T cells

Citation

Wolday, D, Tegbaru, B, Kassu, A, Messele, T, Coutinho, R A, van Baarle, D & Miedema, F 2005, 'Expression of chemokine receptors CCR5 and CXCR4 on CD4+ T cells and plasma chemokine levels during treatment of active tuberculosis in HIV-1-coinfected patients.', Journal of Acquired Immune Deficiency Syndromes, vol. 39, no. 3, pp. 265-271.